Dr Robert Rosenson is a Professor of Medicine and Cardiology at the Icahn School of Medicine and the Director of Metabolism and Lipids for the Mount Sinai Health System. He is an American Board of Internal Medicine-certified cardiologist and a member of numerous cardiovascular organisations and medical societies.
Previously, he completed a Research Fellowship in Lipoprotein Metabolism at the University of Chicago Hospitals in 1990, a Cardiovascular Disease Fellowship at the University of Chicago Medical Center in 1989, and an Internal Medicine Residency at Harvard University Medical School, Brigham and Women's Hospital in 1986. He earned his Medical Degree from Tulane University in 1983.
Internationally recognised for his research, Dr Rosenson focuses on the effects of novel lipid-lowering therapy, hypoglycaemic therapy, and antihypertensive agents on inflammation, thrombogenesis, and rheology. His laboratory was the first to demonstrate that statins reduce pro-inflammatory cytokine production.
